Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD-1 antibody-cytokine fusion protein (Qiyu Biotechnology)
- Development stage
- Preclinical
- Lead developer
- Qiyu Bio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PD-1 antibody-cytokine fusion protein (Qiyu Biotechnology) is an experimental bifunctional biologic being developed by Qiyu Biotechnology (also known as QureBio). The molecule consists of a monoclonal antibody targeting the Programmed Cell Death Protein 1 (PD-1) receptor fused to a cytokine moiety. This design aims to direct cytokine activity specifically to PD-1-expressing cells, such as tumor-infiltrating lymphocytes or exhausted T cells, thereby modulating the immune microenvironment. The candidate is currently in preclinical development for a broad range of indications, including various cancers as well as autoimmune and inflammatory disorders. By utilizing the PD-1 antibody as a targeting vehicle, the therapy seeks to improve the therapeutic index of the attached cytokine, potentially reducing systemic toxicity while enhancing localized efficacy.
- Other names
- QureBio PD-1-antibody-cytokine fusion protein
02
Targets
IL21R (Interleukin-21 receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PD-1 antibody-cytokine fusion protein (Qiyu Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD-1 antibody-cytokine fusion protein (Qiyu Biotechnology).